Rifaximin-伪 550 mg (XIFAXAN;/TARGAXAN;) is effective in reducing the recurrence of episodes of overt HE. Our aim was to determine the cost effectiveness of rifaximin-伪 550 mg versus standard care (lactulose) in patients with cirrhosis in the UK. Method This economic evaluation used a ...
Whitehouse JT, Berni E, Conway P, Radwan A, Henrar R, Currie CJ. Evaluation of the cost effectiveness and societal impact of rifaximin-a 550 mg in the reduction of recurrence of overt hep- atic encephalopathy in The Netherlands. Value Health. 2015;18(7):A629....
Cost Effectiveness of Rifaximin-á 550mg In The Reduction of Recurrence of Overt Hepatic Encephalopathy In United Kingdom[J] . E Berni,CD Poole,P Conway,A Radwan,CJ Currie.Value in Health . 2015 (7)Berni E, Poole CD, Conway P, Radwan A, Currie CJ. Cost effectiveness of rifaximin-α ...
Objective: Rifaximin-alpha 550 mg twice daily plus lactulose has demonstrated efficacy in reducing recurrence of episodes of overt hepatic encephalopathy (OHE) and the risk of hepatic encephalopathy (HE)-related hospitalizations compared with lactulose alone. This analysis estimated the cost effectiveness ...
Cost effectiveness of rifaximin-α 550mg in the reduction of recurrence of overt hepatic encephalopathy in United Kingdom. Value Health. 2015;18:A626 [abstract].Berni E, Poole CD, Conway P, Radwan A, Currie CJ. Cost effective- ness of rifaximin-α 550 mg in the reduction of recurrence of...
Cost effectiveness of rifaximin-α 550mg in the reduction of recurrence of overt hepatic encephalopathy in United Kingdom. Value Health. 2015;18:A626 [abstract].Berni E, Poole CD, Conway P, Radwan A, Currie CJ. Cost effective- ness of rifaximin-α 550 mg in the reduction of recurrence of...
Patients were enrolled for group R + L upon satisfying the above criteria and if financially feasible for the patients (cost: about USD 7600/year). All patients who received rifaximin 550 mg twice daily continuously took lactulose as a combination treatment, and lactulose dosage was adjusted to ...